ANAPTYSBIO, INC 8-K

What Happened
AnaptysBio announced that the Spin‑Off of First Tracks Biotherapeutics was completed on April 20, 2026. The companies executed a Separation and Distribution Agreement and a Transition Services Agreement to divide assets, allocate liabilities, license shared IP and provide limited transition support. Under the split, First Tracks takes the clinical R&D business (rosnilimab, ANB033, ANB101 and related assets), while AnaptysBio retains a “Royalty Management Co.” business holding royalties (including Jemperli and imsidolimab royalties). The companies also documented indemnification, tax allocation rules (including an optional Section 336(e) election), and licenses to allow each business to operate post‑distribution.

Key Details

• Spin‑Off completed: April 20, 2026; pro forma financials to be filed by amendment within four business days.
• Cash and milestones: First Tracks receives $100.0 million in cash at distribution and may be entitled to up to $35.0 million in future Vanda collaboration milestones.
• Transition Services: First Tracks will provide digital tech, HR, supply chain, finance, real estate and other services for up to two years (or shorter by agreement).
• Leadership/board changes: Dennis Fenton, Rita Jain and Magda Marquet resigned from AnaptysBio’s board effective April 20, 2026; J. Anthony Ware resigned effective April 23, 2026. CMO Paul Lizzul left AnaptysBio and became First Tracks’ CMO; CEO Daniel Faga will continue as AnaptysBio’s CEO under a consulting agreement at least through Jan 15, 2027.

Why It Matters
The Spin‑Off separates AnaptysBio’s royalty‑management activities from its former drug‑development operations, creating two focused businesses: a royalty/asset manager (AnaptysBio) and an R&D company (First Tracks). The $100 million cash allocation and milestone rights give First Tracks operating capital for its clinical programs, while AnaptysBio retains ongoing royalty income streams. Transition services and IP licenses are intended to ensure operational continuity; indemnities and tax allocations clarify who bears historical and post‑transaction liabilities. Investors should watch the forthcoming pro forma financials for the separated companies’ capital, liabilities and expected cash flows, and note the board and management changes that follow the split.